- Synthelabo and genomics company Genset have agreed to work together on the discovery and sequencing of genes involved in or associated with prostate cancer. Synthelabo will have rights to develop and sell small molecules, therapeutic proteins and therapeutic antibodies for prostate cancer and other prostate diseases. Genset has rights to antisense oligo-nucleotides, gene and cell therapies, diagnostics and applications other than prostate disease. Synthelabo will fund the program by up to 355 million French francs ($69 million), as well as making a 50 million franc equity investment in Genset.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze